Diagnosed with stage 4 breast cancer weeks after giving birth, Eileen Carter explains why getting a second opinion changed the course of her care.
|Articles|June 30, 2015
Sue Friedman on Informed Decision-Making in Hereditary Breast and Ovarian Cancers
Author(s)Sue Friedman
Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network and the importance of informed decision-making.
Advertisement
Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses
Advertisement
Related to this article
A study found that sentinel lymph node biopsy rarely missed remaining cancer in patients with locally advanced breast cancer whose lymph nodes responded to chemotherapy before surgery.
Lower income, later diagnosis and gaps in treatment drove most of the excess deaths among rural patients, according to new research.
The FDA has cleared TumorSight Risk, software that uses a patient's existing breast MRI, pathology and clinical information to estimate the chance that early HR-positive, HER2-negative breast cancer will come back within five and 10 years.
Emma Halligan found connection at a free New Jersey retreat for women with cancer, which held its annual walk and 5K on Oct. 17.
Twenty-four years after breast cancer, one survivor reflects on mammogram anxiety, the relief of clear results and the gratitude of living beyond cancer.
In a randomized trial of nearly 100,000 women in Germany, 3D mammography found a larger share of breast cancers at the screening visit, but its 24% lower rate of cancers found between screenings was not statistically significant.
Eileen Carter was told she had two to three years to live after a stage 4 breast cancer diagnosis. A second opinion changed her care.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Jemperli for dMMR Locally Advanced Rectal Cancer
2
Diagnosed With Sarcoma at 21, She Found Her People at Mary's Place
3
FDA Clears AI Tool Using MRI to Gauge Breast Cancer Recurrence
4
Gemcitabine Plus BCG Clears Bladder Cancer in 96% of Patients After BCG Failure
5